Bivigam Market Report 2026: Epidemiology, Pipeline Analysis, Market Insights & Forecasts

The growth in the historic period can be attributed to clinical effectiveness of ivig, increased awareness of immunodeficiency disorders, hospital based infusion protocols, expansion of plasma donation networks, regulatory approvals for ivig indications.

The growth in the forecast period can be attributed to rising prevalence of immune disorders, expansion of neurological ivig applications, growth of home infusion models, improved plasma supply chains, aging population trends. Major trends in the forecast period include rising adoption of ivig therapies, growing diagnosis of primary immunodeficiency, expansion of immunoglobulin use beyond pid, improved plasma collection and fractionation processes, increasing demand for long term immune support therapies.

The rising prevalence of immunodeficiency disorders is expected to drive the growth of the bivigam market going forward. Immunodeficiency disorders are conditions in which the immune system’s ability to fight infections and diseases is impaired, either due to genetic factors or external influences such as infections or medical treatments. The prevalence of these disorders is increasing because chronic diseases weaken immune function over time, making individuals more susceptible to infections. Bivigam supports the management of immunodeficiency disorders by providing targeted immune support, making it suitable for patients with weakened immune systems. It helps prevent infections and enhances overall immune function, improving patient health outcomes. For example, in October 2024, the UK Health Security Agency reported 6,008 HIV diagnoses in England in 2023 (including individuals previously diagnosed abroad), representing a 51% increase from 3,975 cases in 2022. Consequently, the rising prevalence of immunodeficiency disorders is contributing to the growth of the bivigam market.

The growing emphasis on personalized medicine is also expected to support the expansion of the bivigam market. Personalized medicine tailors treatments and healthcare decisions to an individual’s unique characteristics, needs, and genetic profile. Rising demand for personalized medicine is driven by advances in genomics, targeted therapies, and the increasing prevalence of chronic diseases that require precise treatment approaches. Personalized medicine enhances Bivigam’s effectiveness by customizing its intravenous immunoglobulin therapy to meet the specific needs of patients, optimizing efficacy in managing primary humoral immunodeficiency. For instance, in February 2024, the Personalized Medicine Coalition, a US-based nonprofit, reported that the FDA approved 16 new personalized therapies for rare disease patients in 2023, up from six in 2022. The approvals also included seven cancer drugs and three treatments for other conditions. Therefore, the growing focus on personalized medicine is driving the bivigam market.

The increasing healthcare expenditure is expected to further propel the growth of the bivigam market. Rising healthcare spending is driven by technological advancements, aging populations, a higher prevalence of chronic diseases, and the growing demand for quality care and personalized treatments. Higher healthcare expenditure enhances access to Bivigam by making immunoglobulin therapies more readily available for patients with immunodeficiency disorders, supporting timely treatment, improved disease management, and better patient outcomes. For example, in May 2024, the UK Office for National Statistics reported that total healthcare expenditure increased by 5.6% in nominal terms in 2023, marking a 0.9% rise compared to 2022. Consequently, rising healthcare expenditure is contributing to the growth of the bivigam market.

Major companies operating in the bivigam market are ADMA Biologics Inc.

North America was the largest region in the bivigam market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the bivigam market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the bivigam market report are Australia, India, China, South Korea, Japan, UK, France, Germany, USA, Canada.

Tariffs have moderately affected the bivigam market by increasing costs related to plasma sourcing, fractionation equipment, and cold chain transportation. These impacts are most visible in hospital and specialty clinic settings. Higher tariffs have contributed to increased ivig therapy costs. At the same time, tariffs are encouraging regional plasma processing investments. This is enhancing long term resilience of immunoglobulin supply chains.

The bivigam market research report is one of a series of new reports that provides bivigam market statistics, including bivigam industry global market size, regional shares, competitors with a bivigam market share, detailed bivigam market segments, market trends and opportunities, and any further data you may need to thrive in the bivigam industry. This bivigam market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Bivigam is an intravenous immune globulin (IVIG) therapy used to treat primary humoral immunodeficiency (PI), a group of disorders in which the immune system fails to produce sufficient antibodies to combat infections. Derived from human plasma, it provides a broad spectrum of antibodies to enhance the immune response in patients with PI.

The primary indications for bivigam include primary immunodeficiency, chronic immune thrombocytopenia (ITP), secondary immunodeficiency, neurological disorders, and other conditions. Primary immunodeficiency refers to a group of genetic disorders in which the immune system is partially or fully impaired, increasing susceptibility to infections, autoimmune diseases, and certain cancers. Bivigam is available as intravenous (IV) and subcutaneous (SC) solutions and is distributed through hospitals, specialty clinics, retail pharmacies, and online pharmacies. The therapy is used by adult, pediatric, and geriatric populations.

The bivigam market consists of sales of intravenous immune globulin (IVIG) therapy products. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.